Ovarian Cancer | Specialty

New Rucaparib Designation, STRIVE Trial, 5-Year Ipilimumab Data, and More

April 12th 2015

Dr. Matulonis on Toxicities With Olaparib for Patients With Ovarian Cancer

April 7th 2015

Ursula A. Matulonis, MD, medical director, gynecologic oncology, Susan F. Smith Center for Women's Cancers, institute physician, Dana-Farber Cancer Institute, discusses managing toxicities associated with olaparib for patients with ovarian cancer.

Rucaparib Receives Breakthrough Designation for BRCA-Positive Advanced Ovarian Cancer

April 6th 2015

The FDA has granted a breakthrough therapy designation to rucaparib as a treatment for women with BRCA-mutated advanced ovarian cancer who have received at least two prior lines of platinum-based chemotherapy.

Fosbretabulin/Bevacizumab Combo Delays Progression, But Doubles Hypertension in Ovarian Cancer

March 31st 2015

Fosbretabulin plus bevacizumab lowered the risk of progression by 31.5% but doubled the rate of hypertension compared with bevacizumab alone in patients with recurrent ovarian cancer.

Bevacizumab Regimen Shows Survival Trend in Phase III Ovarian Cancer Trial

March 30th 2015

Treatment with bevacizumab plus a chemotherapy doublet extended overall survival by nearly 5 months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer.

Autologous Vaccine Delays Progression Following Surgery for Ovarian Cancer

March 30th 2015

Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage III/IV ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not in an open-label phase II trial.

Studies Illuminate Olaparib's Continued Role in Ovarian Cancer

March 30th 2015

Analyses of clinical trials continue to illuminate the role of the PARP inhibitor olaparib in the treatment of women with ovarian cancer, according to Ursula A. Matulonis, MD.

Antiangiogenesis Agents in Ovarian Cancer

March 29th 2015

BJ Rimel, MD, discuss the current literature surrounding antiangiogenesis agents in ovarian cancer.

Dizon Discusses Advantages of IP Chemotherapy for Ovarian Cancer

March 24th 2015

In an interview with OncLive, Don Dizon, MD, explains the advantages of IP therapy and why further research and education are necessary to bring it to the forefront of ovarian cancer treatment.

New Ovarian Cancer Guidelines Include Surgery, Chemotherapy and Therapy Advancements

March 18th 2015

Recent advancements in the treatment of ovarian cancer, including surgical techniques, the approvals of bevacizumab and olaparib, and intraperitoneal chemotherapy, have led the National Comprehensive Cancer Network to make changes to their clinical practice guidelines.

New Therapeutic Target Identified for Ovarian Cancer Subtype

March 18th 2015

Inhibiting EZH2 may improve outcomes in patients with clear cell ovarian carcinoma who harbor a ARID1A mutation.

Challenges in the Treatment of Ovarian and Endometrial Cancers

March 13th 2015

OncLive spoke with Sanaz Memarzadeh, MD, on why ovarian and endometrial cancers are so challenging to treat, and what future research is needed to better understand these diseases.

Analysis Shows Increased Ovarian Cancer Risk From Hormone Replacement Therapy

February 17th 2015

The risk of developing the two most common types of ovarian cancer significantly increases when taking hormone replacement therapy to alleviate symptoms of menopause, according to a meta-analysis of epidemiological studies.

Dr. Wright on Measuring Progression and Recurrence in Ovarian Cancer

February 16th 2015

Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses the challenges in measuring progression and recurrence in patients with ovarian cancer.

Matulonis Discusses Integrating Olaparib Into Clinical Practice

February 16th 2015

To gain insight into the integration of olaparib into clinical practice, OncLive interviewed Ursula A. Matulonis, MD, medical director of gynecologic oncology at Dana-Farber Cancer Institute.

FDA Grants Reolysin Orphan Drug Designation for Ovarian Cancer

February 12th 2015

The FDA has granted an orphan drug designation to Reolysin for the treatment of patients with ovarian cancer.

Role of PARP Inhibitors in Ovarian Cancer Continues to Evolve

February 6th 2015

For insight on the evolving role of PARP inhibitors in the treatment of ovarian cancer, OncLive interviewed Donna McNamara, MD, co-chief of Gynecological Oncology at the John Theurer Cancer Center (JTCC).

Dr. Donna McNamara on PARP Inhibitors for Ovarian Cancer Treatment

January 20th 2015

Donna McNamara, MD, Co-Chief of the Gynecologic Oncology Division and Medical Oncologist for the Breast Oncology Division at the John Theurer Cancer Center, talks about the benefits of PARP inhibitors for women with BRCA1 or BRCA2-mutated, platinum-sensitive ovarian cancer.

Grant Aims to Deliver First Stem-Cell Immunotherapy in Ovarian Cancer

January 19th 2015

The New York State Stem Cell Science Program recently awarded a 4-year $11.9 million grant to Roswell Park Cancer Institute to fund research and development of a stem-cell based treatment for ovarian cancer.

HIPEC for Ovarian Cancer: An Exciting Locoregional Strategy

January 13th 2015

Approximately 22,000 women will be diagnosed with epithelial ovarian cancer (EOC) in the United States in 2014, making it the nation's second most common gynecologic malignancy.1 The cancer, which often presents at an advanced stage, causes more deaths than any other type of gynecologic malignancy.